Teranubia Tablet 100 mg (Sitagliptin phosphate hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
MFDS item code 201503150 · Approved 2015.05.26
This product's status changed to Expired on 2025.05.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. Initially, this medication may be administered alone. If blood sugar control is insufficient with monotherapy, it may be combined with metformin. Additionally, this medication can be added if there is inadequate effect from monotherapy with sulfonylureas, metformin, thiazolidinediones, or insulin. This medication can improve blood sugar control even if multiple types of diabetes treatments are required.
This drug is administered at 100 mg once daily when used as monotherapy or in combination therapy, and the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered without regard to the timing of dialysis.
This medication may cause serious allergic reactions; therefore, if symptoms like skin rash or difficulty breathing occur within 3 months of administration, use should be discontinued immediately. There is a risk of pancreatitis, which is inflammation of the pancreas, so if abdominal pain or vomiting occurs during treatment, the doctor should be informed immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis. In patients with impaired kidney function, the dose should be adjusted and administered cautiously. Cold-like upper respiratory infections, headaches, and symptoms like rhinitis may occur during treatment. Be cautious as the risk of hypoglycemia may increase when combined with other blood sugar-lowering agents, particularly insulin or sulfonylureas. Severe joint pain or blistering conditions resembling dermatitis herpetiformis may occur, and if such symptoms arise, consult a doctor immediately. Pregnant or breastfeeding women should avoid using this medication, and safety in children or adolescents under the age of 18 has not been established. In elderly patients, kidney function may decline, so dose adjustment and kidney function monitoring are necessary. In cases of overdose, general symptomatic treatment should be conducted, and if necessary, some medications can be removed by dialysis. This medication has relatively low interactions with other drugs; however, caution may be needed when used in conjunction with certain medications, so consult a doctor or pharmacist.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air or moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the longevity of its effectiveness.
Beige, round, biconvex film-coated tablet
Company packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.